Prevalence Of Sars-Cov-2 Igg Antibodies In Patients With Cystic Fibrosis In The First 6 Months Of Known Virus In The State Of Mn And Monitoring Of Igg Levels In Follow-Up (6 Months & 1 Year)

Led by Joanne Billings, MD, MPH, associate professor of medicine, Medical School, researchers in this study will evaluate the prevalence of COVID-19 in the CF population in Minnesota during the first six months of known viral presence. "While the extent and devastating effects of COVID-19 on the global community continue to emerge, its effects on the CF community are lacking. Data suggest that COVID-19 in this patient population may be similar to that of the general population but the natural disease course is unknown, including the ability of individuals with CF to mount an effective immune response," said Billings. "We propose to identify those individuals exposed to SARS-CoV-2 as evidenced by antibody production and to monitor IgG antibody levels over a one year period."